Trial · NCT02117713
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA) | MRX Baseline Value | 223.62 | Standard Deviation 205.041 | μmol/L | |
| Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA) | Maralixibat Week 48 Values | 157.35 | Standard Deviation 178.538 | μmol/L | |
| Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA) | Maralixibat Baseline Values | 223.62 | Standard Deviation 205.041 | μmol/L | |
| Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA) | Week 216 | 118.81 | Standard Deviation 126.878 | μmol/L | |
| Change From Baseline to Week 218 in Pruritus | Maralixibat Baseline Values | 2.533 | Standard Deviation 0.8423 | score on a scale | |
| Change From Baseline to Week 218 in Pruritus | Week 218 | 0.429 | Standard Deviation 0.8571 | score on a scale | |
| Change From Baseline to Week 216 in Alanine Aminotransferase | MRX Baseline Value | 152.9 | Standard Deviation 82.26 | U/L | |
| Change From Baseline to Week 216 in Alanine Aminotransferase | Week 216 Values | 222.4 | Standard Deviation 126.53 | U/L | |
| Change From Baseline to End of Treatment in Alkaline Phosphatase | MRX Baseline Value | 598.8 | Standard Deviation 199.89 | U/L | |
| Change From Baseline to End of Treatment in Alkaline Phosphatase | Week 216 Values | 528.3 | Standard Deviation 221.93 | U/L | |
| Change From MRX Baseline to Week 216 in Aspartate Aminotransferase | MRX Baseline Value | 149.7 | Standard Deviation 88.27 | U/L | |
| Change From MRX Baseline to Week 216 in Aspartate Aminotransferase | Week 216 | 231.4 | Standard Deviation 122.26 | U/L | |
| Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score | MRX Baseline Value | 0.9 | Standard Deviation 1.33 | Points | |
| Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score | Week 216 | 1.1 | Standard Deviation 1.68 | Points | |
| Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score | MRX Baseline Value | 2.9 | Standard Deviation 1.08 | Points | |
| Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score | Week 216 | 1.1 | Standard Deviation 1.07 | Points | |
| Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase | MRX Baseline Value | 493.5 | Standard Deviation 380.29 | U/L | |
| Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase | Week 216 Values | 431 | Standard Deviation 235.35 | U/L | |
| Mean Change From MRX Baseline to Week 216 in Total Bilirubin | MRX Baseline Value | 5.62 | Standard Deviation 6.420 | mg/dL | |
| Mean Change From MRX Baseline to Week 216 in Total Bilirubin | Week 216 | 5.39 | Standard Deviation 5.181 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02117713/results